Fosun Pharmaceutical

Fosun Pharma, one of the promoters of Gland Pharma, on Wednesday divested a 6 per cent stake for Rs 1,754 crore through an open market transaction. Chinese drug firm Fosun Pharma, through its arm Fosun Pharma Industrial Pte, offloaded the shares of Hyderabad-based Gland Pharma through a bulk deal on the BSE. According to the bulk deal data available on the BSE, Fosun Pharma Industrial Pte disposed of 99 lakh shares or a 6 per cent stake in Gland Pharma. The shares were sold at an average price of Rs 1,771.81 apiece, taking the deal size to Rs 1,754.09 crore. After the stake sale, Fosun Pharma's shareholding in Gland Pharma has declined to 51.86 per cent from 57.86 per cent. Meanwhile, UBS Principal Capital Asia picked up 8.25 lakh shares, amounting to a 0.5 per cent stake in Gland Pharma. The shares were purchased at an average price of Rs 1,771.05 per piece, taking the transaction value to Rs 146.11 crore. Details of the other buyers of Gland Pharma's shares could not be ...

The merger agreement between Sun Pharma and Taro was approved by an affirmative vote of Taro shareholders at an extraordinary general meeting and an ordinary class meeting on May 22

Speaking to Sohini Das over a video interview from the US, Abhay Gandhi, CEO, North America of Sun Pharma outlines his plan for the company's specialty business

At 7:09 AM, GIFT Nifty futures indicated a modest uptick of 25 points, trading at 22,626 against Nifty futures

The transaction is expected to be completed by the end of February 2024, pending fulfilment of certain conditions

Sun Pharmaceutical Industries Ltd on Wednesday said its arm has entered into a licensing agreement with Aclaris Therapeutics, Inc that includes upfront payment of USD 15 million (about Rs 125 crore), regulatory and commercial milestones, and royalties. The agreement has been signed between Sun Pharmaceutical Industries, Inc Aclaris Therapeutics -- a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, the company said in a regulatory filing. "Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA)," it added. The company further said, "The agreement includes an upfront payment of USD 15 million, regulatory and commercial milestones, and royalties.

The biotech firm has dosed a patient in China with its drug INS018_055 to treat the chronic lung disease idiopathic pulmonary fibrosis

Fosun Pharma holds a 57.86% stake in the Indian company

Pharma shares like Aurobindo Pharma, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals may rise up to 14 per cent.

Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

After the anti-diabetic market, India's cardiac market in for a shake-up

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Gross sales up 10.1% YoY to Rs 10,644 cr; EBITDA at Rs 2,884.4 cr, with a margin of 26.8%

Stocks to watch today: HDFC, Sun Pharma, and Cipla will report their June quarter results on Friday, July 29; Dr Reddy's saw 108 per cent YoY rise in consolidated net profit to Rs 1,187.6 crore in Q1.

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Having consolidated its presence across geographies, the pharma major is looking at acquisitions